Vanda Pharmaceuticals Inc (NASDAQ: VNDA) is 7.10% higher on its value in year-to-date trading and has touched a low of $3.71 and a high of $6.75 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The VNDA stock was last observed hovering at around $4.81 in the last trading session, with the day’s gains setting it 0.32%.
Currently trading at $5.13, the stock is 10.56% and 11.28% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.25 million and changing 6.65% at the moment leaves the stock 1.38% off its SMA200. VNDA registered 11.28% gain for a year compared to 6-month loss of -3.02%.
The stock witnessed a 19.03% gain in the last 1 month and extending the period to 3 months gives it a -0.39%, and is 8.92% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.02% over the week and 4.94% over the month.
Vanda Pharmaceuticals Inc (VNDA) has around 368 employees, a market worth around $299.16M and $198.77M in sales. Fwd P/E is 192.35. Profit margin for the company is -9.51%. Distance from 52-week low is 38.27% and -24.00% from its 52-week high. The company has generated returns on investments over the last 12 months (-3.46%).
The EPS is expected to shrink by -227.27% this year
The shares outstanding are 58.31M, and float is at 54.24M with Short Float at 6.86%.
The top institutional shareholder in the company is BLACKROCK INC. with over 8.14 million shares valued at $45.98 million. The investor’s holdings represent 14.0895 of the VNDA Shares outstanding. As of 2024-06-30, the second largest holder is RENAISSANCE TECHNOLOGIES LLC with 4.11 million shares valued at $23.24 million to account for 7.1227 of the shares outstanding. The other top investors are VANGUARD GROUP INC which holds 3.43 million shares representing 5.9412 and valued at over $19.39 million, while TANG CAPITAL MANAGEMENT LLC holds 3.6985 of the shares totaling 2.15 million with a market value of $12.17 million.
Vanda Pharmaceuticals Inc (VNDA) Insider Activity
A total of 0 insider transactions have happened at Vanda Pharmaceuticals Inc (VNDA) in the last six months, with sales accounting for 0 and purchases happening 0 times. The most recent transaction is an insider purchase by Polymeropoulos Mihael Hristos, the company’s President and CEO. SEC filings show that Polymeropoulos Mihael Hristos bought 10,000 shares of the company’s common stock on Mar 05 ’25 at a price of $5.02 per share for a total of $50200.0. Following the purchase, the insider now owns 2.29 million shares.
Vanda Pharmaceuticals Inc disclosed in a document filed with the SEC on Mar 03 ’25 that Polymeropoulos Mihael Hristos (President and CEO) bought a total of 10,000 shares of the company’s common stock. The trade occurred on Mar 03 ’25 and was made at $4.71 per share for $47050.0. Following the transaction, the insider now directly holds 2.28 million shares of the VNDA stock.
Still, SEC filings show that on Feb 28 ’25, Polymeropoulos Mihael Hristos (President and CEO) acquired 10,000 shares at an average price of $4.76 for $47600.0. The insider now directly holds 2,361,730 shares of Vanda Pharmaceuticals Inc (VNDA).
Vanda Pharmaceuticals Inc (VNDA): Who are the competitors?
One of the company’s main competitors (and peers) include Eli Lilly & Co. (LLY) that is trading 19.23% up over the past 12 months.Johnson & Johnson (JNJ) lies in the list of competitors of the Vanda Pharmaceuticals Inc and is 3.63% higher over the same period from VNDABristol Myers Squibb Co. (BMY) is 12.06% up on the 1-year trading charts.
